Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease

Movement Disorders

Volumn 28, Issue 8, 2013, Pages 1064-1071

  Warren Olanow, C ^a,b   Kieburtz, Karl ^c   Rascol, Olivier ^d   Poewe, Werner ^e   Schapira, Anthony H ^f   Emre, Murat ^g   Nissinen, Helena ^h   Leinonen, Mika ⁱ   Stocchi, Fabrizio ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Scientific Institute for Care and Treatment   (Italy)

^c UNIVERSITY OF ROCHESTER   (United States)

^d UNIVERSITÉ DE TOULOUSE   (France)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g ISTANBUL UNIVERSITY   (Turkey)

^h ORION CORPORATION   (Finland)

ⁱ 4Pharma AB ^*  (Sweden)

Author keywords

Dyskinesia; Entacapone; Levodopa; Parkinson's disease; Wearing off

Indexed keywords

LEVODOPA;

ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; DYSKINESIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NORTH AMERICA; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE;

DYSKINESIA; ENTACAPONE; LEVODOPA; PARKINSON'S DISEASE; WEARING-OFF;

AGED; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEVODOPA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS; TIME FACTORS;

EID: 84881558752     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25364     Document Type: Article

References (20)

1. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
2. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-687.
3. Chase TN, Baronti F, Fabbrini G, Heuser IJ, Juncos JL, Mouradian MM. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 1989;39(11 suppl 2):7-10; discussion 19.
4. Olanow W, Schapira AH, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trend Neurosci 2000;23(10 suppl):S117-S126.
5. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-910.
6. Sage JI, Trooskin S, Sonsalla PK, Heikkila R, Duvoisin RC. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 1988;24:87-89.
7. Nilsson D, Hansson LE, Johansson K, Nystrom C, Paalzow L, Aquilonius SM. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease. Acta Neurol Scand 1998;97:175-183.
8. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 1994;44(5):913-919.
9. Smith LA, Jackson MJ, Al-Barghouthy G, et al. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 2005;20:306-314.
10. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010;68:18-27.
11. Kuoppamaki M, Korpela K, Marttila R, et al. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four- or five-times daily. Eur J Clin Pharmacol 2009;65:443-455.
12. Bonetti M, Gelber RD. Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics 2004;5:465-481.
13. Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson's disease revisited-clinical features, natural history, and mortality. Mov Disord 1998;13:885-894.
14. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991;41(2 pt 1):202-205.
15. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000;123(pt 11):2297-2305.
16. Grandas F, Galiano ML, Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol 1999;246: 1127-1133.
17. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
18. Sharma JC, Ross IN, Rascol O, Brooks D. Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. Eur J Neurol 2008;15:493-496.
19. Muller T, Woitalla D, Saft C, Kuhn W. Levodopa in plasma correlates with body weight of parkinsonian patients. Parkinsonism Relat Disord 2000;6:171-173.
20. Smith LA, Jackson MJ, Hansard MJ, Maratos E, Jenner P. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure. Mov Disord 2003;18:487-495.